$BIIB 3 SEC Filings

Filed On	Filing
12 Aug 2026	Form 3: Parini Michael, Chief Legal Officer No securities owned
06 Apr 2026	Form 3: Biogen Inc., See footnotes · Apellis Pharmaceuticals, Inc. Holds 0 shares of Common Stock
10 Mar 2025	Form 3: Godbout Sean, Chief Accounting Officer Holds 310 shares of Common Stock
07 Jan 2025	Form 3: Pangalos Menelas N, Director Holds 0 shares of Common Stock
07 Oct 2024	Form 3: Minor Lloyd, Director Holds 0 shares of Common Stock
09 Jan 2024	Form 3: Patolawala Monish D, Director Holds 0 shares of Common Stock
12 Oct 2023	Form 3: Grogan Jane, Head of Research Holds 0 shares of Common Stock
07 Aug 2023	Form 3: Biogen Inc., See footnotes · REATA PHARMACEUTICALS INC Holds 0 shares of Class A common stock
28 Jun 2023	Form 3: Langer Susan, Director Holds 459.1 shares of Common Stock
25 Apr 2023	Form 3: Keeney Adam, Head of Corporate Development Holds 0 shares of Common Stock
17 Jan 2023	Form 3: Singhal Priya, Head of Development Holds 1,529.3923 shares of Common Stock
21 Nov 2022	Form 3: Viehbacher Christopher, Director Holds 7,000 shares of Common Stock
14 Feb 2022	Form 3: Murphy Nicole, Head of Pharm Ops and Tech Holds 1,225.89 shares of Common Stock
29 Jul 2021	Form 3: Izzar Rachid, Head of Alzheimer's Disease Holds 899 shares of Common Stock
29 Jun 2021	Form 3: Freire Maria C, Director Holds 0 shares of Common Stock
29 Jun 2021	Form 3: Jones William D /CA/, Director Holds 0 shares of Common Stock
11 Jan 2021	Form 3: Biogen Inc., 10% owner and 1 other · Sage Therapeutics, Inc. Holds 6,241,473 shares of Common Stock
28 Sep 2020	Form 3: Biogen Inc., 10% owner and 1 other · Denali Therapeutics Inc. Holds 13,310,243 shares of Common Stock
20 Aug 2020	Form 3: Mcdonnell Michael R, EVP, Chief Financial Officer Holds 0 shares of Common Stock
22 Apr 2020	Form 3: Biogen Inc., 10% owner and 1 other · Sangamo Therapeutics Inc Holds 24,420,157 shares of Common Stock

Comments